Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unemployment is high in this population, and even among those employed, individuals are often working below their skills and abilities 220,221 .”
From Autism spectrum disorder (2020) · cites this paper as [221]
In the citing paper
“However, several drug development programs based on the inhibition of mGluR signaling for the treatment of FXS (Novartis and Seaside Therapeutics) were recently closed because efficacy studies in adolescents and adults showed no measurable benefits 114,115 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [114]
In the citing paper
“Exploratory biomarkers and endophenotypes tested in a substudy (n = 56) of the mavoglurant trials suggests an improvement relative to placebo in gaze towards the eye region on an eye-tracking task and in performance on a computerized executive function battery69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Mild side effects (headaches, dizziness, insomnia and vomiting) were observed in about 20% of FXS patients with mavoglurant at higher dose levels69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Conversely, the larger studies of mavoglurant, basimglurant and arbaclofen included over 100 participants and were able to provide conclusions across secondary outcome measures69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
(1985) · PubMed · Cited by 1,427
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Reliability and validity of a computerized neurocognitive test battery, CNS vital signs
GUALTIERI, C., & JOHNSON, L. (2006) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2006.05.007 · Cited by 873 · cited 1×
“CNS VS TheCNSVS is a computerized testing battery focused onworkingmemory; the following four modules were used: Visual Memory Test (VIM), Symbol-Digit Coding (SDC), Perception of Emotions Test (POET), and three-part Continuous Performance Test (CPT) [WorkingMemory Test (WMT)] (31).”
MethodLam, K. S. L., & Aman, M. G. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0213-z · Cited by 793
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.-P., & Mandel, J.-L. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 780 · cited 1×
“This mutation is associated with complete or partial methylation at the FMR1 promoter, resulting in the loss or significant reduction of expression of the gene product FMRP (fragile X mental retardation protein) (7).”
Background
Research works printed but not linked: 2
- W. Guy in ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health Psychopharmacology Research Branch Mental Health Administration Rockville MD 1976) pp. 217–222.
- 10.1176/jnp.12.2.233 · DOI · Paper page
Cited by
Items 101–200 of 282
Glutamatergic synapse in autism: a complex story for a complex disorder
Galineau, L., Arlicot, N., Dupont, A.-C., Briend, F., Houy‐Durand, E., Tauber, C., Gomot, M., Gissot, V., Barantin, L., Lefèvre, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01860-9 · Cited by 27
“Two mGluR5 negative allosteric modulators (basimglurant, mavoglurant) have been evaluated in subjects with FXS [16–18], but no therapeutic benefits have been reported for unclear reasons yet.”
BackgroundInfluentialBruno, J. L., Romano, D., Mazaika, P. K., Lightbody, A. A., Hazlett, H. C., Piven, J., & Reiss, A. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620994114 · Cited by 26
“Although several targeted therapies have demonstrated promising phenotype rescue in animal models (6–8), they have been unsuccessful thus far in human trials (9).”
BackgroundStrategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 32
Pellerin, D., Lortie, A., & Corbin, F. (2017) · Platelets · doi:10.1080/09537104.2017.1317733 · Cited by 25
Zerbi, V., Markicevic, M., Gasparini, F., Schroeter, A., Rudin, M., & Wenderoth, N. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.02.051 · Cited by 25
“In humans, deficits in associated circuits have been found in both FXS and ASD subjects, and linked to common symptoms such as sensory hypersensitivity, and deficits in attention and sociability (Baron-Cohen et al., 2009; Gallagher and Hallahan, 2012) (Hall et al., 2013; Reig and Silberberg, 2016; Wilson, 2014).”
BackgroundResultInfluentialEffects of AFQ056 on language learning in fragile X syndrome
Berry‐Kravis, E., Abbeduto, L., Hagerman, R. J., Coffey, C. S., Cudkowicz, M., Erickson, C. A., McDuffie, A. S., Hessl, D. R., Ethridge, L. E., Tassone, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171723 · Cited by 26
“17, N=140; RO4917523 age 14+, N=183) (22, 23) were conducted with primary outcomes of the Aberrant Behavior Checklist-Community Edition (FXS scoring algorithm, ABCFX, Novartis) (24) and the Anxiety, Depression and Mood Scale (ADAMS (23), Roche).”
Self-citationCremers, S., & Aronson, J. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13331 · Cited by 25
A brain proteomic investigation of rapamycin effects in the Tsc1 +/− mouse model
Wesseling, H., Elgersma, Y., & Bahn, S. (2017) · Molecular Autism · doi:10.1186/s13229-017-0151-y · Cited by 26
“[80, 81] and PKCG inhibitors could represent a novel”
BackgroundMcGraw, C. M., Ward, C. S., & Samaco, R. C. (2017) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31570 · Cited by 24
“The ABCCFX scores were also shown to be highly susceptible to placebo effect over the course of the clinical trials (Berry-Kravis et al., 2016).”
BackgroundZeidler, S., de Boer, H., Hukema, R. K., & Willemsen, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00368 · Cited by 26
“Some randomized, placebo controlled clinical trials with the mGluR5 antagonists mavoglurant/AFQ056, fenobam (Berry-Kravis et al., 2009, 2016; Jacquemont et al., 2011) and basimglurant (Youssef et al., 2017) have been performed.”
BackgroundSato, A., & Ikeda, K. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.08.005 · Cited by 25
“Despite the clinical expectations based on preclinical results, no therapeutic efficacy was found in randomized clinical trials with FXS participants who were treated with the selective mGlu5 inhibitor mavoglurant (125) and GABAB receptor agonist arbaclofen (126).”
BackgroundShaffer, R. C., Reisinger, D. L., Schmitt, L., Lamy, M., Dominick, K. C., Smith, E. G., Coffman, M. C., & Esbensen, A. J. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.06.020 · Cited by 25
Ramos-Prats, A., Kölldorfer, J., Paolo, E., Zeidler, M., Schmid, G., & Ferraguti, F. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00030 · Cited by 22
“The “mGlu5 receptor theory of FX” was recently tested in several phase II, placebo controlled, clinical trials, which, however, did not achieve significant efficacy in the primary end point of improvement on behavioral symptoms (Berry-Kravis et al., 2016; Youssef et al., 2018).”
MethodRescue of Fmr1 phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056
Westmark, P. R., Dekundy, A., Gravius, A., Danysz, W., & Westmark, C. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.008 · Cited by 22
Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study
Budimirovic, D. B., Dominick, K. C., Gabis, L. V., Adams, M., Adera, M., Huang, L., Ventola, P. E., Tartaglia, N. R., & Berry‐Kravis, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.757825 · Cited by 22
Self-citationHaessler, F., Gaese, F., Huß, M., Kretschmar, C., Brinkman, M., Peters, H., Elstner, S., Colla, M., & Pittrow, D. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1020-5 · Cited by 22
“For example, the mavoglurant studies had applied, among others, the SRS scale to identify the presence of autistic social impairment; the TEA-Ch to test every-day attention and inhibition in children; or the widely used Clinical Global Impression (CGI) scale to assess treatment response in psychiatric patients [42].”
Self-citationFragile X syndrome clinical trials: exploring parental decision‐making
D'Amanda, C. S., Peay, H. L., Wheeler, A., Turbitt, E., & Biesecker, B. B. (2019) · Journal of Intellectual Disability Research · doi:10.1111/jir.12605 · Cited by 21
Arsova, A., Møller, T. C., Vedel, L., Hansen, J. L., Foster, S. R., Gregory, K. J., & Bräuner‐Osborne, H. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.119032 · Cited by 20
“In patients with fragile X syndrome, neither basimglurant nor mavoglurant showed efficacy in reversing behavioral deficits (Berry-Kravis et al., 2016; Youssef et al., 2018).”
BackgroundKroon, T., Dawitz, J., Kramvis, I., Anink, J. J., Obermayer, J., Verhoog, M. B., Wilbers, R., Goriounova, N. A., Idema, S., Baayen, J. C., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00315 · Cited by 20
Heterogeneity in Fragile X Syndrome Highlights the Need for Precision Medicine-Based Treatments
Verdura, E., Pérez‐Cano, L., Sabido-Vera, R., Güney, E., Hyvelin, J.-M., Durham, L. A., & Gomez‐Mancilla, B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.722378 · Cited by 20
Berry‐Kravis, E. (2022) · Journal of Child Neurology · doi:10.1177/08830738221089740 · Cited by 21
Self-citationFragile X Syndrome: Prevalence, Treatment, and Prevention in China
Niu, M., Han, Y., Dy, A. B. C., Du, J., Jin, H., Qin, J., Zhang, J., Li, Q., & Hagerman, R. J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00254 · Cited by 22
Self-citationCorrection of amygdalar dysfunction in a rat model of fragile X syndrome
Fernandes, G., Mishra, P. K., Nawaz, M. S., Donlin-Asp, P., Rahman, M. M., Hazra, A., Kedia, S., Kayenaat, A., Songara, D., Wyllie, D. J. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109805 · Cited by 23
“For example, a randomized, double-blind, placebo-controlled trial using a selective mGluR5-antagonist did not reveal any significant effect on emotional function in FXS patients (Berry-Kravis et al., 2016).”
BackgroundAnimal models of neurodevelopmental disorders with behavioral phenotypes
Harris, J. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000675 · Cited by 21
“A clinical trial of the mGluR5 antagonist mavoglurant (AFQ056), in fragile X syndrome based on promising results in mutant mouse models, ended with negative results in large international clinical trials that involved adults and adolescents [12].”
BackgroundChronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice
Cogram, P., Alkon, D., Crockford, D., Deacon, R., Hurley, M., Altimiras, F., Sun, M.-K., & Tranfaglia, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74848-6 · Cited by 9
Brašić, J. R., Nandi, A., Russell, D., Jennings, D. L., Barret, O., Mathur, A., Slifer, K. J., Sedlak, T. W., Martin, S., Brinson, Z. S., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10120899 · Cited by 19
Self-citationHardan, A. Y., Jo, B., Frazier, T. W., Klaas, P., Busch, R. M., Dies, K. A., Filip‐Dhima, R., Snow, A. V., Eng, C., Hanna, R., et al. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100733 · Cited by 16
Bruno, J. L., Hosseini, S. M. H., Lightbody, A. A., Manchanda, M. K., & Reiss, A. L. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858304 · Cited by 16
“Results of human treatment trials aimed at correcting aberrant glutamatergic (Berry-Kravis et al., 2016; Jacquemont et al., 2011) or GABAergic signaling (Berry-Kravis et al.”
Targeting mGlu5 for Methamphetamine Use Disorder
Petzold, J., Szumlinski, K. K., & London, E. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107831 · Cited by 16
A novel eye‐tracking paradigm for indexing social avoidance‐related behavior in fragile X syndrome
Klusek, J., Moser, C., Schmidt, J., Abbeduto, L., & Roberts, J. E. (2019) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32757 · Cited by 15
“For example, preliminary findings from a recent Novartis AFQ056 phase 2 FXS clinical trial suggest that eye-tracking indices revealed treatment effects whereas traditional caregiverreported behavioral ratings did not (Berry-Kravis et al., 2016; Hessl et al., 2019).”
ResultNeurodevelopment and early pharmacological interventions in Fragile X Syndrome
Milla, L. A., López‐Corral, L., Rivera, J., Zúñiga, N., Pino, G., Nunez-Parra, A., & Rio, C. A. C.-D. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1213410 · Cited by 15
“It is worth notice, that these PET studies were performed in FXS adult patients between 18 and 60 years old, which may explain the unsuccessful results in mGluR5 antagonist clinical trials that have addressed a similar age range (Bailey et al., 2015; Berry-Kravis et al., 2016; Youssef et al., 2018).”
BackgroundResultRouzade‐Dominguez, M., Pezous, N., David, O. J., Tutuian, R. I., Varannes, S. B. D., Tack, J. F., Malfertheiner, P., Allescher, H. D., Ufer, M., & Rühl, A. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13058 · Cited by 15
Reines, V., Charen, K. H., Rosser, T. C., Eisen, A., Sherman, S. L., & Visootsak, J. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0111-x · Cited by 15
Self-citationMarsillo, A., David, L., Gerges, B. F. N., Kerr, D. J., Sadek, R., Lasiychuk, V., Salame, D., Soliman, Y., Menkes, S., Chatterjee, A., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166048 · Cited by 20
Baker, E. K., Arpone, M., Kraan, C. M., Bui, M., Rogers, C., Field, M. J., Bretherton, L., Ling, L., Ure, A. M., Cohen, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-68465-6 · Cited by 15
Kos, J. A., Langiu, M., Hellyer, S. D., & Gregory, K. J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00213 · Cited by 16
Perche, O., Lesne, F., Patat, A. A., Raab, S., Twyman, R. E., Ring, R. H., & Briault, S. (2021) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09375-0 · Cited by 13
Graziani, D., Caligari, S., Callegari, E., Toma, C. D., Longhi, M., Frigerio, F., Dilernia, R., Menegon, S., Pinzi, L., Pirona, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01226 · Cited by 16
Felts, A. S., Rodriguez, A. L., Morrison, R. D., Bollinger, K. A., Venable, D. F., Blobaum, A. L., Byers, F. W., Gray, A. T., Daniels, J. S., Niswender, C. M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.09.042 · Cited by 13
Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
Hagerman, R. J., & Hagerman, P. J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-090147 · Cited by 15
Self-citationLi, R., Bruno, J. L., Jordan, T. L., Miller, J. G., Lee, C. H.-Y., Bartholomay, K. L., Marzelli, M., Piccirilli, A. M., Lightbody, A. A., & Reiss, A. L. (2021) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.09.003 · Cited by 12
Grabb, M. C., & Potter, W. Z. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001553 · Cited by 14
Electrophysiological Biomarkers in Genetic Epilepsies
Armstrong, C., & Marsh, E. D. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01132-4 · Cited by 14
Rare variants in the outcome of social skills group training for autism
Li, D., Olsson, N. C., Becker, M., Arora, A., Jiao, H., Norgren, N., Jonsson, U., Bölte, S., & Tammimies, K. (2021) · Autism Research · doi:10.1002/aur.2666 · Cited by 13
“83 Nevertheless, few studies are focused on investigating how genetic information or genetically 84 defined subgroups of autistic individuals can be used to guide the choice or development of 85 treatments and interventions for ASD [10].”
BackgroundFRAGILE X SYNDROME AND PREMUTATION‐ASSOCIATED DISORDERS
Hagerman, R. J. (2020) · Wiley eBooks · doi:10.1002/9781119432692.ch28 · Cited by 12
Self-citationmGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS
Kumar, V., Lee, K. Y., Acharya, A., Babik, M. S., Christian, C. A., Rhodes, J. S., & Tsai, N. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00038-w · Cited by 11
“…unfortunate failure of clinical trials, such as the one for the negative allosteric modulator (NAM) against mGluR5, Mavoglurant (Scharf et al, 2015; Berry-Kravis et al, 2016), has prompted the search for alternative therapeutic strategies. mGluR7, an understudied mGluR, belongs to group III mGluRs…”
Petroni, V., Subashi, E., Premoli, M., Memo, M., Lemaire, V., & Pietropaolo, S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.917183 · Cited by 11
“, 2022), together with its predictive validity (Berry-Kravis et al., 2016).”
BackgroundGenetic Approaches to Understanding Psychiatric Disease
Michaelson, J. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0551-x · Cited by 11
Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome
Rogers, T. D., Anacker, A. M. J., Kerr, T. M., Forsberg, C. G., Wang, J., Zhang, B., & Veenstra-VanderWeele, J. M. (2017) · Molecular Autism · doi:10.1186/s13229-017-0148-6 · Cited by 11
“Although improvement of behavioral and synaptic abnormalities was observed in animal models following treatment with mGluR5 negative allosteric modulators [49, 50], clinical trials have not yet yielded benefit in adolescents or adults with FXS [51].”
BackgroundFelts, A. S., Bollinger, K. A., Brassard, C. J., Rodriguez, A. L., Morrison, R. D., Daniels, J. S., Blobaum, A. L., Niswender, C. M., Jones, C. K., Conn, P. J., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.017 · Cited by 11
D’Antoni, S., Schiavi, S., Buzzelli, V., Giuffrida, S., Feo, A., Ascone, F., Busceti, C. L., Nicoletti, F., Trezza, V., & Catania, M. V. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06457-w · Cited by 11
“Despite initial positive results and extensive preclinical research, clinical trials have failed to confirm beneficial effects in FXS patients (Jacquemont et al. 2011; Berry-Kravis et al. 2016; reviewed by Scharf et al. 2015; Emmitte 2017; Witkin et al. 2022).”
ResultTranslating genetic and preclinical findings into autism therapies
Chahrour, M. H., Kleiman, R. J., & Manzini, M. C. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.4/cmanzini · Cited by 13
Advancing precision diagnosis in autism: Insights from large-scale genomic studies
Kim, S.-W., & An, J. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100248 · Cited by 14
Targeted Treatments for Fragile X Syndrome
Johnson, D., Clark, C. J., & Hagerman, R. J. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_10 · Cited by 10
Self-citationJmaeff, S., Sidorova, Y. A., Lippiatt, H., Barcelona, P. F., Nedev, H. N., Saragovi, L. M., Hancock, M. A., Saarma, M., & Saragovi, H. U. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.118950 · Cited by 10
Harris, J. C., & Coyle, J. T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00016-2 · Cited by 12
Galambos, J., Bielik, A., Wágner, G., Domány, G., Kóti, J., Béni, Z., Szigetvári, Á., Sánta, Z., Orgován, Z., Bobok, A. Á., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.071 · Cited by 10
Fragile X Syndrome and Targeted Treatments
Tassanakijpanich, N., Cabal-Herrera, A. M., Salcedo‐Arellano, M. J., & Hagerman, R. J. (2020) · Journal of Biomedicine and Translational Research · doi:10.14710/jbtr.v6i1.7321 · Cited by 10
Self-citationFMR1 mutant marmosets show fragile X syndrome phenotypes
Harbers, M., Wei, Z., Nakao, H., Abe, Y., Goto, M., Tamano, M., Sakai, Y., Shimizu, K., Nakao, K., Sugaya, Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116208 · Cited by 11
Budimirovic, D. B., & Duy, P. Q. (2015) · Engrami · doi:10.5937/engrami1504005b · Cited by 10
The mGluR Theory of Fragile X: From Mice to Men
Stoppel, L. J., Osterweil, E. K., & Bear, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00009-3 · Cited by 14
The Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities
Romagnoli, A., & Marino, D. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.754485 · Cited by 14
Medishetti, R., Rani, R., Kavati, S., Mahilkar, A., Akella, V., Saxena, U., Kulkarni, P., & Sevilimedu, A. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106656 · Cited by 10
Hunt, J. F. V., Li, M., Risgaard, R. D., Ananiev, G. E., Wildman, S. A., Zhang, F., Bugni, T. S., Zhao, X., & Bhattacharyya, A. (2021) · Cells · doi:10.3390/cells11010069 · Cited by 9
Abbeduto, L., Soriano, L. D. H., Berry‐Kravis, E., Sterling, A. M., Edgin, J. O., Abdelnur, N., Drayton, A., Hoffmann, A., Hamilton, D., Harvey, D. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36087-3 · Cited by 8
Self-citationStudying child development in genetic models of ASD
Garg, S., & Green, J. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.009 · Cited by 9
Psychopharmacology of Neurodevelopmental Disorders in Children
Singh, J., & Santosh, P. (2016) · Springer eBooks · doi:10.1007/978-81-322-3619-1_18 · Cited by 9
Ramesh, V., Tsoukala, E., Kougianou, I., Kozić, Z., Burr, K., Viswanath, B., Hampton, D. W., Story, D., Reddy, B. K., Pal, R., et al. (2025) · Glia · doi:10.1002/glia.24680 · Cited by 7
“…mechanisms underlying neuronal dysfunction, proposed neuron-focused treatments have not produced robust results in large clinical trials so far (Berry-Kravis et al. 2022, 2017, 2016; Youssef et al. 2018; Ligsay et al. 2017), while the contribution of glia in FXS pathophysiology remains largely…”
Emerging autism and Fragile X syndrome treatments
Parkhill, M., Salmaso, N., D’Angiulli, A., Lee, V., & Aguilar‐Valles, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.02.004 · Cited by 7
Protic, D. D., Breeze, E., Mendoza‐Morales, G., Zafarullah, M., Abbeduto, L., Hagerman, R. J., Coffey, C. S., Cudkowicz, M., Durbin-Johnson, B. P., Ashwood, P., et al. (2024) · SAGE Open Medicine · doi:10.1177/20503121241282401 · Cited by 8
“29,30 An additional sub-study conducted within the Phase 2b trial did indicate that the drug engaged with its intended target.”
BackgroundSelf-citationEley, S. E. A., McKechanie, A. G., Campbell, S., & Stanfield, A. C. (2020) · Journal of Intellectual Disability Research · doi:10.1111/jir.12779 · Cited by 7
“It is notable that the largest clinical trials that have occurred in FXS have required multinational efforts to recruit a relatively small number of participants (Berry‐Kravis et al., 2016; Hagerman et al., 2018; Youssef et al., 2018).”
BackgroundWatkins, L. V., Moon, S., Burrows, L., Tromans, S. J., Barwell, J., & Shankar, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2323605 · Cited by 7
“This review identified one article including two studies or cohorts with similar design (adolescent cohort and adult cohort) [30].”
BackgroundFrom Discovery to Innovative Translational Approaches in 80 Years of Fragile X Syndrome Research
van der Lei, M. B., & Kooy, R. F. (2025) · Biomedicines · doi:10.3390/biomedicines13040805 · Cited by 9
“However, it failed to show statistically significant differences from placebo in primary caregiver-rated outcomes in clinical trials [138,139].”
Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders
Srivastava, S., Şahin, M., & Prock, L. A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00022-9 · Cited by 9
Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research
Neul, J. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175036 · Cited by 7
“…three phase 2b studies of these compounds in adolescents and adults with FXS characterized efficacy of these mGluR5 NAMs on behavioral features (10, 11), all of which failed to show efficacy and had large placebo effects, although post hoc analyses showed evidence of target engagement (3).”
BackgroundInsights into the Structural Aspects of the mGlu Receptor Orthosteric Binding Site
Hao, J., & Chen, Q. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011094935 · Cited by 6
Shaffer, R. C., Thurman, A. J., Ronco, L. V., Cadavid, D., Raines, S. R., & Kim, S. H. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-021-09411-z · Cited by 9
“There are no approved treatments for FXS, and very few therapeutic clinical trials in FXS have been conducted with positive results by either industry or academic investigators [4, 6, 19, 24, 60].”
BackgroundFolsom, T. D., Higgins, L., Markowski, T. W., Griffin, T. J., & Fatemi, S. H. (2018) · Synapse · doi:10.1002/syn.22069 · Cited by 6
Yang, S.-T., Wang, M., Galvin, V. C., Yang, Y., & Arnsten, A. F. T. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05661-2 · Cited by 7
“However, clinical trials of mGluR5NAMs in adolescents and adults with Fragile X syndrome have failed to ameliorate behavioral symptoms (Berry-Kravis et al. 2016; Berry-Kravis et al. 2018).”
BackgroundHuman Pluripotent Stem Cells in Modeling Human Disorders: the Case of Fragile X Syndrome
Vershkov, D., & Benvenisty, N. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0100 · Cited by 6
Westmark, C. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00029 · Cited by 6
“With regard to the urgent need to validate outcome measures for FXS clinical trials, recent trials failed on primary endpoints (Berry-Kravis et al., 2013, 2016).”
From Genes to Therapy in Autism Spectrum Disorder
Vorstman, J. A. S., Freitag, C. M., & Persico, A. M. (2022) · Genes · doi:10.3390/genes13081377 · Cited by 6
Thom, R. P., Warren, T. L., Khan, S., Muhle, R., Wang, P. P., Brennand, K., Zürcher, N. R., Veenstra-VanderWeele, J. M., & Hoffman, E. J. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2025.0023 · Cited by 5
“…ef fi cacy for behavioral outcomes as measured by the Aberrant Behavior Checklist FXS-speci fi c algorithm (ABC-C(FX)) total score compared with placebo in adults or adolescents (Berry-Kravis et al., 2016), nor did a follow-up study focusing on language learning in preschool-aged children with FXS.”
Therapeutic strategies for fragile X syndrome and implications for other gene-silencing disorders
Gadban, A., Gunapala, K. M., Taylor, V., & Benvenisty, N. (2025) · Nature Genetics · doi:10.1038/s41588-025-02255-6 · Cited by 6
“However, inhibitors of metabotropic glutamate receptor 5 (mGluR5), mavoglurant (AFQ056) 45 and basimglurant (RG-7090) 46,47 , failed in FXS clinical trials, as they failed to show significant effects.”
Applying biologically anchored subtypes to advance precision medicine in autism spectrum disorder
Choi, T.-Y., Gunawan, A., Seo, D., Park, J., Ahn, E. H., Suh, S. W., Fuccillo, M. V., & Choi, K. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107219 · Cited by 5
Ciranna, L., & Costa, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062495 · Cited by 6
“Past clinical trials targeting metabotropic glutamate receptors have shown no significant improvements on Fragile X patients [100–102].”
Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome
Munshi, K. R., Pawlowski, K. G., Gonzalez–Heydrich, J., & Picker, J. D. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0200 · Cited by 7
“Based on these findings, there followed two American and European Union RCTs involving fully and partially methylated individuals with FXS, one in adults and one in adolescents (Berry-Kravis et al. 2016).”
Budimirovic, D. B., & Duy, P. Q. (2017) · Madridge Journal of Neuroscience · doi:10.18689/mjns-1000101 · Cited by 5
Katsnelson, A. (2018) · Lab Animal · doi:10.1038/laban.1394 · Cited by 6
Unraveling a pathway to autism
Burbach, J. P. H. (2016) · Science · doi:10.1126/science.aaf5097 · Cited by 5
Lai, M., Anagnostou, E. A., Wiznitzer, M., Allison, C. L., & Baron‐Cohen, S. (2018) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/8z5rv · Cited by 7
“Large RCTs of mGluR5 inhibitors failed to show effects on social function despite early promising human and animal studies (Berry-Kravis et al., 2016).”
BackgroundLye, V., Hassiotis, A., Timmerman, A., Alqazlan, S., Dimitrova, E., Vegh, B., & Totsika, V. (2025) · BJPsych Open · doi:10.1192/bjo.2025.10871 · Cited by 4
“7) were associated with a non-significant effect size Study Acosta et al (2019) 31 Berry-Kravis et al (2016) 42 Berry-Kravis et al (2017) 43 Blasi et al (2020) 32 Efron et al (2020) 45 Fastman et al (2021) 46 Johnson et al (2019) 33 Kostulski et al (2021) 34 Overwater et al (2019) 48 Royston et al…”
Human pluripotent stem cell (hPSC)-derived models for autism spectrum disorder drug discovery
Nie, L., Irwin, C. L., Geahchan, S., & Singh, K. K. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2416484 · Cited by 4
“However, highly successful preclinical drug candidates in rodent studies have shown mixed effectiveness in follow-up clinical trials [105–109], suggesting that these models may not fully recapitulate human FXS pathology.”
Overview of Targeted Double-Blind, Placebo-Controlled Clinical Trials in Fragile X Syndrome
Ligsay, A., Hagerman, R. J., & Berry‐Kravis, E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00019-6 · Cited by 4
Self-citationHarkins, C. M., Dominick, K. C., Wink, L. K., Pedapati, E. V., Shaffer, R. C., Fitzpatrick, S. E., Davenport, M. H., Sweeney, J. A., & Erickson, C. A. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0199-1 · Cited by 4
“This finding prompted further efficacy studies utilizing molecular profiling to identify differential treatment response in individuals with complete versus partial methylation of the FMR1 promotor [33].”
BackgroundProgress in rehabilitation equipment for autism spectrum disorder
Hou, R., Yang, C., Tao, C., & Fan, Y. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100365 · Cited by 4
Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Telias, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191102165206 · Cited by 4
Modeling Fragile X Syndrome Using Human Pluripotent Stem Cells
Vershkov, D., Ben‐Hur, T., & Benvenisty, N. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804461-2.00006-8 · Cited by 5
Felts, A. S., Rodriguez, A. L., Morrison, R. D., Blobaum, A. L., Byers, F. W., Daniels, J. S., Niswender, C. M., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.053 · Cited by 4
Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
Alusi, G., Berry‐Kravis, E., Nelson, D. L., Orefice, L. L., & Booker, S. A. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00674 · Cited by 4
Self-citation
Metadata
- Authors
- Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F.
- Affiliations
- Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
- National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
- University of California Davis Medical Center (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Emory University (US)
- Novartis (Germany) (DE)
- Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
- Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
- Novartis (United States) (US)
- Universitätsklinikum Tübingen (DE)
- Novartis (Switzerland) (CH)
- Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-01-13
- Volume
- 8
- Issue
- 321
- Pages
- 321ra5-321ra5
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2237631658
- Cited by
- 270
- References
- 35
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 23 · 2021: 21 · 2020: 35 · 2019: 29 · 2018: 27 · 2017: 54 · 2016: 22
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- fragile X syndrome, metabotropic glutamate receptor 5, mGluR5 antagonist, intellectual disability, autism spectrum disorder, behavioral symptoms, synaptic plasticity, drug safety and efficacy
- MeSH terms
- Adolescent, Adult, Age Factors, Behavior, Cognition, Demography, Double-Blind Method, Female, Fragile X Syndrome, Humans, Indoles, Male, Placebos, Least-Squares Analysis, Treatment Outcome, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.